uBriGene Biosciences
Shanghai, CN · Boston, MA
11 partnership announcements in press monitoring
· Last scored 2026-09-07
56.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (20)
○ EMA GMP
○ MHRA GMP
Quick Facts: uBriGene Biosciences
- Signal Score
- 56.5/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Shanghai, CN · Boston, MA
- Modalities
- AAV, Lentiviral, Plasmid
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About uBriGene Biosciences
Chinese CGT CDMO with US presence. BIOSECURE Act exposure.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 11 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Partnership Announcements (from press monitoring)
Financial Stability
50.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
63.0
Profile-based capacity assessment
Recent Press20 articles
Recent News 20 articles
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Digital Journal
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Digital Journal
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Corsicana Daily Sun
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies corsicanadailysun.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - The Facts
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies The Facts
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Weatherford Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Weatherford Democrat
uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies - National Today
uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies National Today
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - PharmiWeb.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies PharmiWeb.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Yahoo Finance
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Yahoo Finance
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - News-Press NOW
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies News-Press NOW
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - The Batesville Daily Guard
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies The Batesville Daily Guard
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Carroll County Mirror-Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Carroll County Mirror-Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Scott Coop
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Scott Coop
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Newswire.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies newswire.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene - pharmiweb.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene PharmiWeb.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Rutland Herald
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy Rutland Herald
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - BioSpace
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy BioSpace
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Weatherford Democrat
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy weatherforddemocrat.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - ACCESS Newswire
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy ACCESS Newswire
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - guardonline.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy The Batesville Daily Guard
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - newswire.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy newswire.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - theglobeandmail.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy The Globe and Mail
Frequently Asked Questions About uBriGene Biosciences
What is uBriGene Biosciences's CDMO Signal Score?
uBriGene Biosciences has a Signal Score of 56/100, based on quality, operations, financial stability, and capacity data.
Evaluating uBriGene Biosciences for a manufacturing program?
Use the free AI matchmaker to compare uBriGene Biosciences against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 81.0
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid
Ascend Advanced Therapies
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Plasmid